Prescription Event Monitoring in Patients With Benign Prostatic Hyperplasia (BPH)
NCT ID: NCT02244346
Last Updated: 2014-09-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
811 participants
OBSERVATIONAL
2004-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety Profile of Secotex ® in Patients With Benign Prostatic Hyperplasia
NCT02245529
Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
NCT01939184
Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH)
NCT01454349
Botulinum Toxin Injection for the Management of BPH
NCT00451191
A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo
NCT00224107
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Benign prostatic hyperplasia patients
Secotex®
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Secotex®
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with symptoms, that according to physician require medical treatment to improve quality of life
* Patients could be naive to treatment or could be on treatment with other drugs but have not responded adequately to treatment
Exclusion Criteria
* Patients with a history of orthostatic hypotension or severe liver failure
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boehringer Ingelheim
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
527.58
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.